牛牛AI助理已提取核心訊息
Tharimmune, Inc., a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq Stock Market under the trading symbol THAR, has filed a Form 8-K current report with the United States Securities and Exchange Commission (SEC) on February 8, 2024. The report confirms that as of the same date, Tharimmune had a total of 11,739,676 shares of common stock issued and outstanding. The company, which is classified as an emerging growth company, has not changed its name or address since the last report. The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by an authorized representative of Tharimmune, Inc.
Tharimmune, Inc., a biopharmaceutical company incorporated in Delaware and listed on the Nasdaq Stock Market under the trading symbol THAR, has filed a Form 8-K current report with the United States Securities and Exchange Commission (SEC) on February 8, 2024. The report confirms that as of the same date, Tharimmune had a total of 11,739,676 shares of common stock issued and outstanding. The company, which is classified as an emerging growth company, has not changed its name or address since the last report. The filing was made in accordance with the requirements of the Securities Exchange Act of 1934 and was signed by an authorized representative of Tharimmune, Inc.
Tharimmune, Inc. 是一家在特拉華州註冊並在納斯達克股票市場上市、交易代碼爲THAR的生物製藥公司，已於2024年2月8日向美國證券交易委員會（SEC）提交了8-K表最新報告。該報告證實，截至同日，Tharimmune共發行和流通了11,739,676股普通股。該公司被列爲新興成長型公司，自上次報告發布以來一直沒有更改其名稱或地址。該文件是根據1934年《證券交易法》的要求提交的，由Tharimmune, Inc.的授權代表簽署。
Tharimmune, Inc. 是一家在特拉華州註冊並在納斯達克股票市場上市、交易代碼爲THAR的生物製藥公司，已於2024年2月8日向美國證券交易委員會（SEC）提交了8-K表最新報告。該報告證實，截至同日，Tharimmune共發行和流通了11,739,676股普通股。該公司被列爲新興成長型公司，自上次報告發布以來一直沒有更改其名稱或地址。該文件是根據1934年《證券交易法》的要求提交的，由Tharimmune, Inc.的授權代表簽署。
有用
沒用